Sutro Biopharma Inc stock is traded at $10.26, with a volume of 138,935. It is up +0.88% in the last 24 hours and down -22.74% over the past month. Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Previous Close:
$10.17
Open:
$10.35
24h Volume:
138,935
Relative Volume:
0.58
Market Cap:
$170.12M
Revenue:
$99.61M
Net Income/Loss:
-$153.60M
P/E Ratio:
-
EPS:
-$16.45
Net Cash Flow:
-$152.14M
1W Performance:
+11.52%
1M Performance:
-22.74%
6M Performance:
-74.92%
1Y Performance:
+26.53%
1-Day Range:
$9.94$10.36
1-Week Range:
$9.22$10.77
52-Week Range:
$7.15$43.85
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma IncSector
HealthcareIndustry
BiotechnologyPhone
650-392-8412Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS